4-Oxo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-2-carboxylic acid, 95.0%, 5g

4-Acetoxybenzoic acid, 98.0%, 25g

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazole, 95.0%, 250mg

(2S,4R)-1-(tert-Butoxycarbonyl)-4-(prop-2-yn-1-yl)pyrrolidine-2-carboxylic acid, 95.0%, 250mg

4-Bromo-2-ethoxythiazole, 95.0%, 5g

3-Bromo-4-(methylamino)benzoic acid, 95.0%, 250mg

2-(2-Fluorophenyl)-5,5-dimethyl-1,3,2-dioxaborinane, 95.0%, 10g

Oxion Inverso OX.2453-PLPHF avec objectifs LWD Plan fluarex 10x et plan phase fluarex 20x/40x, blocs filtrants 4 positions et table croisée XY

Acétate de zinc, min 95%, pur, anhydre, 100 g, emballage plastique.

Methyl 4-((diethoxyphosphoryl)methyl)benzoate, 98%, 1g

5-Fluoro-2-methylphenylacetic acid, 95.0%, 25g

Sodium 3-Morpholinopropanesulfonate>98.0%(T)25g

1,1-CYCLOPROPANEDICARBOXAMIDE, N-[4-[[2-[(CYCLOPROPYLCARBONYL)AMINO]-4-PYRIDINYL]OXY]-2,5-DIFLUOROPHENYL]-N'-(4-FLUOROPHENYL)-, 95%, 25mg